Table 3 Previous studies about ovarian preservation in endometrial cancer patients
Study | Year | Country | Period | Patients | Age | Stage | Grade | Histology | Follow up period (month) | Survival benefits |
|---|---|---|---|---|---|---|---|---|---|---|
Wright | 2009 | USA | 1988–2004 | 402/2867 | 45 | Ia 64%, Ib 33%, Ic 3% | I 79%, II 14%, III 3% | endo | 1–121 | NS |
Lee | 2009 | Korea | 1993–2005 | 123/− | 45 | Ia 74%, Ib 23%, Ic 3% | I 70%, II 17%, III 2% | Endo (86%) | 1–125 | No recur, 5-yr OS:98% |
Sun | 2012 | China | 2002–2010 | 34/132 | 45 | Ia 71%, Ib 22%, Ic 7% | I 70%, II 20%, III 10% | Endo (97%) | 27–122 | NS |
Lee | 2013 | Korea | 1997–2008 | 176/319 | Ia 89% Ib 5% II 6% | I 78% II 18% III 4% | endo | 6–208 | NS | |
Wright | 2016 | USA | 1998–2012 | 1121/14527 | < 50 | Ia 89% Ib 8% II 3% | I 60% II 27% III 6% | endo | 61, median | NS |
Wang | 2016 | China | 2009–2015 | 25/76 | < 45 | Ia 87%, Ib 13% | I 75%, II 21%, III 40% | Endo (99%) | NS |